Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Raf

RAF kinases are a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes. The mouse sarcoma virus 3611 contains a RAF kinase-related oncogene that enhances fibrosarcoma induction. RAF is an acronym for Rapidly Accelerated Fibrosarcoma. RAF kinases participate in the RAS-RAF-MEK-ERK signal transduction cascade, also referred to as the mitogen-activated protein kinase (MAPK) cascade. Activation of RAF kinases requires interaction with RAS-GTPases.

LXH254
T118981800398-38-2
LXH254 is a B C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.
  • $48
In Stock
Size
QTY
Sorafenib
T0093L284461-73-0
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6 22 90 15 20 20 57 58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Regorafenib
T1792755037-03-7
Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
PLX-4720
T2473918505-84-7
PLX-4720 is a potent and selective B-Raf (V600E) inhibitor designed to block the ATP-binding site of oncogenic B-Raf with IC50 of 13 nM.
  • $32
In Stock
Size
QTY
Dabrafenib
T19031195765-45-7
Dabrafenib (GSK2118436A) is a Raf inhibitor that inhibits C-Raf and B-RafV600E (IC50=5 0.6 nM) and is ATP-competitive. Dabrafenib exhibits antitumor activity for the treatment of B-RafV600E-mutated melanoma.
  • $41
In Stock
Size
QTY
TargetMol | Citations Cited
Vemurafenib
T2382918504-65-1
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31 48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
  • $50
In Stock
Size
QTY
TargetMol | Citations Cited
Pepinh-TRIF TFA
T76089
Pepinh-TRIF TFA is a 30 aa peptide associated with the immune system that blocks TRIF signaling by interfering with TLR-TRIF interaction (TLR-TRIF interaction ).
  • $128
In Stock
Size
QTY
Encorafenib
T64871269440-17-6
Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
  • $47
In Stock
Size
QTY
TargetMol | Citations Cited
Xl-281
T68170870603-16-0In house
Xl-281 (BMS-908662) is a BRAF inhibitor with anti-tumor activity for the study of colorectal cancer and melanoma.
  • $293
In Stock
Size
QTY
Dabrafenib Mesylate
T84741195768-06-9
Dabrafenib Mesylate (GSK2118436 Mesylate) is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).
  • $40
In Stock
Size
QTY
RAS GTPase inhibitor 1
T126922252242-32-1In house
RAS GTPase inhibitor 1 is a RAS GTPase inhibitor with potential antitumor activity.
  • $373 TargetMol
In Stock
Size
QTY
TargetMol | Citations Cited
Exarafenib
T636442639957-39-2
Exarafenib (RAF KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.
  • $131
In Stock
Size
QTY
GSK1904529A
T60031089283-49-7In house
GSK1904529A (GSK 4529) is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) .
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Doramapimod
T6277285983-48-4
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
TAK-580
T68951096708-71-2
TAK-580 (MLN2480) is an oral, selective pan-Raf kinase inhibitor in Clinicalal trials.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Sale
AZ 628
T6318878739-06-1
AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.
  • $38
In Stock
Size
QTY
GDC-0879
T6320905281-76-7
GDC-0879 (AR-00341677) is a novel, potent and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well.
  • $32
In Stock
Size
QTY
Ro 5126766
T6971946128-88-7
RO5126766 (CH5126766) is a dual RAF MEK inhibitor with IC50 of 8.2 nM, 19 nM, 56 nM, and 160 nM for BRAF V600E, BRAF, CRAF, and MEK1, respectively. Phase 1.
  • $52
In Stock
Size
QTY
TargetMol | Inhibitor Sale
GW 441756
T6052504433-23-2
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
  • $51
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Sorafenib tosylate
T0093475207-59-1
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6 20 22 nM for Raf-1 VEGFR-3 B-Raf).
  • $37
In Stock
Size
QTY
TargetMol | Citations Cited
Pluripotin
T6948839707-37-8
Pluripotin (SC1) (SC1), which keep embryonic stem cell (ESC) self-renewal, is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP.
  • $30
In Stock
Size
QTY
PLX8394
T35791393466-87-9
Plixorafenib (PLX8394) is an orally active inhibitor of the serine threonine protein kinase B-Raf (BRAF) protein.Plixorafenib can selectively bind to and inhibit the activity of wild-type and mutant forms of BRAF, inhibiting the proliferation of tumor cells expressing mutant forms of BRAF.
  • $44
In Stock
Size
QTY
BAY-293
T54182244904-70-7
BAY-293 is a potent, cell-active SOS1 inhibitor that disrupts the KRAS-SOS1 interaction (IC50: 21 nM).
  • $48
In Stock
Size
QTY
MRTX0902
T97552654743-22-1
MRTX0902 is an effective and high selective inhibitor of SOS1 with an IC50 of 46 nM and a Ki of 2 nM.
  • $87
In Stock
Size
QTY
TargetMol | Inhibitor Sale
ARS-853
T74141629268-00-3
ARS-853 is an inhibitor of K-RASG12C(IC50 : 2.5 μM), a mutant form of K-RAS that accumulates in the active GTP-bound state in certain cancer cells
  • $153
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Sulindac sulfide
T1303749627-27-2In house
Sulindac sulfide (cis-Sulindac sulfide) is a non-steroidal anti-inflammatory compound that has a high affinity for COX-1 and acts as an inhibitor in Ras activation of Raf-1. Sulindac sulfide is a non-competitive inhibitor of gamma-secretase with an IC50 value of 20.2 μM. It is an active metabolite of sulinic acid.
  • $31
In Stock
Size
QTY
SB-590885
T2295405554-55-4
SB590885 is an effective B-Raf inhibitor (Ki: 0.16 nM, in a cell-free assay). The selectivity of SB590885 for B-Raf is 11-fold greater over c-Raf, no acts to other human kinases.
  • $36
In Stock
Size
QTY
TargetMol | Citations Cited
GW 5074
T6525220904-83-6
GW 5074 (Raf1 Kinase Inhibitor I)(IC50=9 nM) is an effective and specific c-Raf inhibitor. It has no effect on the activities of JNK1 2 3, MEK1, MKK6 7, CDK1 2, c-Src, p38 MAP, VEGFR2 or c-Fms.
  • $36
In Stock
Size
QTY
TargetMol | Citations Cited
NVP-BHG712
T6348940310-85-0
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
  • $31
In Stock
Size
QTY
Lonafarnib
T6302193275-84-2
Lonafarnib (Sch66336) is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B, and N-ras (IC50: 1.9 5.2 2.8 nM).
  • $41
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Donafenib
T169091130115-44-4
Donafenib (Bay 43-9006 (D3)) is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).
  • $84
In Stock
Size
QTY
Plx-4032
T86541029872-54-5
Plx-4032 (Vemurafenib) is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
  • $50
In Stock
Size
QTY
Regorafenib Hydrochloride
T8402835621-07-3
Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
  • $30
In Stock
Size
QTY
Indirubin
T6169479-41-4
Indirubin (Couroupitine B) is a potent inhibitor of cyclin-dependent kinases and GSK-3β, with IC50 values of approximately 5 µM and 0.6 µM, respectively.
  • $45
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Belvarafenib
T56341446113-23-0
Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Pelitinib
T2327257933-82-7
Pelitinib (EKB-569) (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
  • $43
In Stock
Size
QTY
TargetMol | Citations Cited
SGX-523
T22931022150-57-7
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
  • $44
In Stock
Size
QTY
TargetMol | Citations Cited
CCT241161
T96381163719-91-2In house
CCT241161 is an orally active pan-RAF inhibitor, with IC50 values of 3, 6, 10, 15, and 30 nM for LCK, CRAF, SRC, V600E-BRAF, and BRAF, respectively. It exhibits significant activity against BRAF and NRAS mutant melanomas and demonstrates anticancer cell proliferative effects [1].
  • $139
In Stock
Size
QTY
LY3009120
T68821454682-72-4
LY3009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 values of 44 nM for A-raf, 31-47 nM for B-Raf, and 42 nM for C-Raf in A375 cells. Phase 1.
  • $30
In Stock
Size
QTY
Rineterkib
T112241715025-32-3
Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1 2 activating mutations in the MAPK pathway.
  • $96
In Stock
Size
QTY
TargetMol | Citations Cited
Regorafenib monohydrate
T1792L1019206-88-2
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.
  • $30
In Stock
Size
QTY
GSK2008607
T274541244644-50-5In house
GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
  • $350
In Stock
Size
QTY
RAF265
T6296927880-90-8
RAF265 (CHIR-265) (CHIR-265) is a potent selective inhibitor of C-Raf B-Raf B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM. Phase 2.
  • $39
In Stock
Size
QTY
RMC-0331
T381702488788-52-7
RMC-0331 (RM-023) is an orally available and potent SOS1 inhibitor with potential anticancer activity, blocking RAS activation by disrupting RAS-SOS1 interactions.
  • $148
In Stock
Size
QTY
BI-882370
TQ00481392429-79-6
BI-882370 is a specific RAF kinase inhibitor. BI-882370 inhibits the oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases (IC50s: 0.4, 0.8 and 0.6 nM). BI-882370 also inhibits SRC family kinases.
  • $36
In Stock
Size
QTY
NVP-BAW2881
T3641861875-60-7
NVP-BAW2881 (BAW2881) is a potent and selective VEGFR (vascular endothelial growth factor receptor tyrosine kinase) inhibitor with efficacy in inhibiting chronic and acute skin inflammation.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
NST-628
T870413002056-30-3
NST-628 is a pan-RAF-MEK molecular glue that prevents RAF from phosphorylating and activating MEK, inhibiting the RAF-MEK signaling complex.
  • $223
In Stock
Size
QTY
CCT196969
T41331163719-56-9
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale